CoChat

Effect of Daily Aspirin on Long-Term Risk of Death Due to Cancer: Analysis of Individual Patient Data From Randomized Trials

Rothwell, Peter M., Fowkes, F. Gerald R., Belch, Jill F. F., Ogawa, Hisao, Warlow, Charles P., Meade, Tom W. · 2011 · Obstetrical & Gynecological Survey
Cited by 69

The DOI matches its Crossref record.

Abstract

Daily treatment with aspirin for longer than 5 years reduces the long-term risk of colorectal cancer. A number of studies have suggested that long-term aspirin use may reduce the risk of several noncolorectal solid cancers, but clear evidence for a preventive effect is lacking. This study investigated the possible effect of aspirin on reducing the risk of fatal cancer among patients with gastrointestinal and nongastrointestinal cancers. Data were obtained from randomized trials with aspirin, originally conducted on prevention of vascular events. Eligible trials with median duration of scheduled trial treatment of at least 4 years were identified in the medical literature. Pooled results comparing the effect of aspirin and controls on deaths due to cancer showed 674 deaths due to cancer among 25,570 patients; aspirin significantly reduced the risk of cancer deaths (odds ratio, 0.79; 95% confidence interval [CI], 0.68–0.92; P = 0.003). Analysis of data on time of death available from 7 trials (23,535 patients, 657 cancer deaths) showed that a reduction in risk of death was apparent only after 5 years' follow-up for all cancers (hazard ratio [HR], 0.66; 95% CI, 0.50–0.87) and gastrointestinal cancers (HR, 0.46; 0.27–0.77; P values for both = 0.003). Three posttrial follow-up studies on the 20-year risk of death due to cancer (1634 deaths in 12,659 patients) showed that the reduction in risk by aspirin treatment compared with controls remained lower for all solid cancers (HR, 0.80; 95% CI, 0.72–0.88; P < 0.0001) and gastrointestinal cancer (HR, 0.65; 95% CI, 0.54–0.78; P < 0.0001). The greatest benefit was found with scheduled duration of trial treatment of ≥7.5 years for solid cancers (P = 0.003) and gastrointestinal cancers (P = 0.0001). Reductions in risk of death due to esophageal, pancreatic, brain, and lung cancer were evident only after a latent period of 5 years, whereas reductions in deaths due to stomach, colorectal, and prostate cancer were not observed until about 10 years. The benefit on the 20-year risk of death was limited to certain cancers, especially adenocarcinomas of lung (P = 0.04) and esophagus (P = 0.0001). The absolute reduction in risk of death due to cancer at 20 years increased with age, reaching 7.08% (95% CI, 2.42–11.74) at age 65 years or more. No increased benefit was found for aspirin doses greater than 75 mg daily and the effect was unrelated to gender or smoking. These findings provide evidence that daily aspirin reduces the risk of death due to several common noncolorectal cancers during and after the trials, with consistent effects across different populations and benefit increasing with duration of treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/ogx.0b013e318225cec2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 69

Metadata

Authors
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F. F., Ogawa, H., Warlow, C. P., & Meade, T. W.
Venue
Obstetrical & Gynecological Survey
Published
2011-04
Volume
66
Issue
4
Pages
222-223
ISSN
0029-7828 (ISSN-L)
OpenAlex
W2320901702
Cited by
69
References
0
FWCI
8.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Daily Aspirin on Long-Term Risk of Death Due to Cancer: Analysis of Individual Patient Data From Randomized Trials. https://app.cochat.ai/papers/10.1097/ogx.0b013e318225cec2
The paper
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of Daily Aspirin on Long-Term Risk of Death Due to Cancer: Analysis of Individual Patient Data From Randomized Trials. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0b013e318225cec2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.